You searched for "Prostatitis"
Cystoplasty
Case 1 A 48-year-old female, having previously had an augmentation ileocystoplasty 10 years ago, has been referred with right loin pain by the emergency department. A venous blood gas is performed shortly after triage with the following values: What is...Redundant! Do urological surgeons have a future in treating urological cancers? RSM Urology Section Meeting
December 2023 marked the latest RSM Urology Section event. Alongside the Winter Short Papers Prize presentations, the theme of the day was major urological cancers and the role of the urologist in patient management within the multidisciplinary team (MDT). We...Introduction to virtual healthcare job interviews
What’s the best way to run a video job interview? Matthew Wu and Elliott Kozin provide some top tips – both for interviewer and interviewee. The ongoing COVID-19 pandemic has changed almost every aspect of society. For the foreseeable future,...APAM (Association of Physicians of Great Britain and Ireland) 118th Annual Meeting 2025
Welcome to APAM 2025 - What Awaits? APAM 2025, the 118th Annual Meeting of the AoPGBI, will take place on 3–4 April 2025 at the Royal College of Physicians in London. This prestigious event will bring together leading clinicians, researchers,...NHS Greater Glasgow and Clyde Prostate Cancer Nurse Specialist wins Continence and Urology Nurse of the Year at BJN Awards 2025
Leann McLaughlin, a Uro-Oncology CNS who specialises in prostate cancer at Inverclyde Royal Hospital, NHS Greater Glasgow and Clyde, has won Urology and Continence Nurse of the Year at the British Journal of Nursing (BJN) Awards 2025. The prestigious event...Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...
Defining adjuvant, consolidative, and salvage treatment after RP
The most common oncologic outcome following radical prostatectomy (RP) for localised prostate cancer is achieving undetectable prostate-specific antigen (PSA) levels (<0.1 ng/ml), indicating an absence of detectable disease. However, the landscape of RP is shifting as active surveillance becomes the...Meeting in the middle: a review of the rendezvous technique to treat impassable ureteric strictures and transected ureters
Introduction Complex ureteric strictures present a significant challenge with some patients undergoing multiple separate urological and radiological procedures to try to cross a stricture without success. Cross-departmental collaboration with uroradiology may allow a decrease in the number of separate interventions....Prostate cancer management 1 – non-metastatic disease
You are referred a 68-year-old gentleman to the rapid access prostate clinic with a serum prostate specific antigen (PSA) of 12ug/L. He is otherwise fit and well with mild voiding lower urinary tract symptoms (LUTS). He undergoes a multi parametric...
